Evaluation of an aminobisphosphonate (alendronate) in the management of periodontal osseous defects

H R Veena, Deepak Prasad, H R Veena, Deepak Prasad

Abstract

Background and objectives: Alendronate, an aminobisphosphonate, is capable of inhibiting periodontitis associated osteoclastic activity and hence is effective in protecting the alveolar bone in periodontitis. In the present study, we explored the efficacy of local delivery of alendronate on the alveolar bone following mucoperiosteal flap surgery. This is the first study to use polymer impregnated gel based delivery of alendronate.

Materials and methods: A total of 15 patients with chronic periodontitis in the age group of 35 - 55 years, of both sexes, with pocket depth of ≥ 5mm and radiographic evidence of identical osseous defects in the mandibular molar region bilaterally were included in this prospective study. A gel based drug delivery system of Alendronate was formulated. Following surgical flap debridement, 0.1 ml alendronate gel and 0.1 ml placebo gel was placed at the experimental and control sites respectively. Clinical and radiographic parameters were recorded at baseline, three months and six months post surgery.

Results: Alendronate was more effective in improving clinical and radiographic parameters compared to placebo.

Interpretation and conclusion: Alendronate is effective in the management of periodontitis associated bone loss. Gel based local delivery of the drug addresses the critical concern of exposing the patient to adverse effects of systemic administration.

Keywords: Alendronate/therapeutic use; alveolar bone loss; bisphosphonates/therapeutic use; bone resorption; osteoclasts; surgical flaps.

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Pocket depth measurement
Figure 2
Figure 2
Method of recording linear radiographic measurements
Figure 3
Figure 3
Osseous defect
Figure 4
Figure 4
Placement of alendronate gel
Graph 1
Graph 1
Postoperative changes in gingival index
Graph 2
Graph 2
Postoperative changes in probing pocket depth
Graph 3
Graph 3
Postoperative changes in clinical attachment level
Figure 5
Figure 5
Radiograph of experimental site at baseline
Figure 6
Figure 6
Radiograph of experimental site at 3 months
Figure 7
Figure 7
Radiograph of experimental site at 6 months
Graph 4
Graph 4
Mean changes in radiographic parameters between the two sites at 3 months
Graph 5
Graph 5
Mean changes in radiographic parameters between the two sites at 6 months

References

    1. Binderman I, Adut M, Yaffe A. Effectiveness of local delivery of Alendronate in reducing alveolar bone loss following periodontal surgery in rats. J Periodontol. 2000;71:1236–40.
    1. Martin TJ, Grill V. Bisphosphonates-mechanisms of action. Aust Prescr. 2000;23:130–2.
    1. Meraw SJ, Reeve CM, Wollan PC. Use of alendronate in peri-implant defect regeneration. J Periodontol. 1999;70:151–8.
    1. Fleisch H. Bisphosphonates: Mechanisms of action. Endocr Rev. 1998;19:80–100.
    1. Frinkleman RD. Local delivery of chemotherapeutic agents in periodontal therapy: Has its time arrived? J Clin Periodontol. 1998;25:943–6.
    1. Bergenholtz A, Al-Harbi N, Al-Hummayani FM, Anton P, Al-Kahtani S. The accuracy of the Vivacare true pressure sensitive periodontal probe system in terms of probing force. J Clin Periodontol. 2000;27:93–8.
    1. Philstrom BL. Periodontal risk assessment, diagnosis and treatment planning. Periodontology 2000. 2001;25:37–58.
    1. Jeffcoat MK, Chung-Wang I, Reddy MS. Radiographic diagnosis in Periodontics. Periodontology 2000. 1995;7:54–68.
    1. Whaites E, Cawson RA. Singapore: Longman Singapore Publishers (Ltd); 1992. Essentials of Dental radiography and radiology; pp. 59–77.
    1. Rocha M, Nava LE, Torre CV, Marin FS, Sevilla EG, Malacara JM. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with Alendronate: A randomized, placebo controlled trial. J Periodontol. 2001;72:204–9.
    1. Reddy MS, Weatherford TW, Smith AC. Alendronate treatment of naturally occurring periodontitis in beagle dogs. J Periodontol. 1995;66:211–7.
    1. Brunsvold MA, Chaves ES, Kornman KS, Aufdemorte TB, Wood R. Effects of Bisphosphonate on experimental periodontitis in monkeys. J Periodontol. 1992;63:825–30.
    1. Kaynak D, Meffert R, Gunhan M, Gunhan O, Ozkaya O. A histopathological investigation on the effects of the bisphosphonate alendronate on resorptive phase following mucoperiosteal flap surgery in the mandible of rats. J Periodontol. 2000;71:790–6.
    1. Yaffe A, Golomb G, Breuer E, Binderman I. The effect of topical delivery of novel bisacyl phosphonates in reducing alveolar bone loss in the rat model. Periodontol. 2000;71:1607–12.
    1. Weinreb M, Quartucchio H, Seedor JG. Histomorphometrical analysis of the effects of the bisphosphonate Alendronate on bone loss caused by experimental periodontitis in monkeys. J Periodont Res. 1994;29:35–40.
    1. Woo SB, Hellstein JW, Kalmar JR. Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006;144:753–6. [Erratum, Ann Intern Med 2006;145:235.]
    1. Masoodi NA. Oral bisphosphonates and the risk for osteonecrosis of the Jaw. BJMP. 2009;2:11–5.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren